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ABSTRACT
Objective: Thyroid volume and the prevalence of thyroid nodules are higher in patients with insu-
lin resistance. A relationship between thyroid volume and glucose metabolism disorders (GMD) 
has not as yet been clarified. The present retrospective study aimed to investigate the association 
between GMD and thyroid volume. Subjects and methods: We investigated the data of 2,630 
patients who were evaluated for thyroid biopsy in our hospital. The study population included 602 
patients with GMD, 554 patients with diabetes mellitus (DM) and 1,474 patients with normal gluco-
se metabolism as a control group. We obtained the levels of serum thyroid stimulating hormone 
(TSH) and the thyroid volumes of those patients retrospectively. Results: The median ages for the 
control group, GMD group and DM group were 55 (15-91) years, 60 (27-97) years, and 65 (27-91) 
years respectively and there was a statistically significant difference between the groups with 
regard to age and gender (p < 0.001). Levels of TSH were similar in all groups. The median total 
thyroid volumes for patients with DM and GMD were significantly higher than that of the control 
group [22.5 (3-202) mL, 20.2 (4-190) mL, and 19.2 (3-168) mL respectively, p ≤ 0.001 for all para-
meters]. Also the median total thyroid volume for patients with DM was significantly higher than 
that of the GMD group (p < 0.001). According to the correlation analysis, thyroid volume was sig-
nificantly correlated with age (r = 0.92, p < 0.001) and TSH (r = 0.435, p < 0.001). Age, gender, TSH 
levels, GMD and DM diagnosis were independently correlated with thyroid volume. Conclusion: 
The thyroid gland is one of the target tissues of metabolic disorders. We reported a positive corre-
lation between GMD/type 2 DM and thyroid volume. Further controlled, prospective, randomized 
studies on this subject are required to gain more information. Arq Bras Endocrinol Metab. 2014;58(8):824-7 
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RESUMO 
Objetivo: O volume da tiroide e a prevalência de nódulos tiroidianos são mais altos em pacientes 
com resistência à insulina. A relação entre o volume da tiroide e os transtornos do metabolismo da 
glicose (TMG) ainda não foi elucidada. O objetivo do presente estudo retrospectivo foi investigar a 
associação entre os TMG e o volume da tiroide. Sujeitos e métodos: Analisamos os dados de 2.630 
pacientes que foram avaliados para biópsia de tiroide em nosso hospital. A população estudada 
incluiu 602 pacientes com TMG, 554 pacientes com diabetes melito (DM) e 1.474 pacientes com me-
tabolismo normal da glicose, como grupo controle. As concentrações de hormônio tireoestimulante 
(TSH) e os volumes da tiroide para esses pacientes foram obtidos de forma retrospectiva. Resulta-
dos: As idades medianas para o grupo controle, grupo TMG e grupo DM foram 55 (15-91), 60 (27-97) 
e 65 (27-91) anos, respectivamente, e houve diferença estatisticamente significativa entre os grupos 
com relação à idade e ao gênero (p < 0,001). Os níveis de TSH foram similares em todos os grupos. 
A mediana do volume total da tiroide para pacientes com DM e TMG foi significativamente maior do 
que para os pacientes do grupo controle [22,5 (3-202) mL, 20,2 (4-190) mL, e 19,2 (3-168) mL, respecti-
vamente, p ≤ 0,001 para todos os parâmetros]. Além disso, a mediana do volume total da tiroide para 
pacientes com DM foi significativamente maior do que no grupo TMG (p < 0,001). De acordo com 
a análise de correlação, o volume da tiroide foi significativamente correlacionado com a idade (r = 
0,92; p < 0,001) e TSH (r = 0,435; p < 0,001). A idade, o gênero, a concentração de TSH e o diagnóstico 
de TMG e DM se correlacionaram com o volume da tiroide de forma independente. Conclusão: A 
tiroide é um dos tecidos-alvo para doenças metabólicas. Relatamos uma correlação positiva entre 
TMG/DM tipo 2 e o volume da tiroide. São necessários mais estudos prospectivos, randomizados e 
controlados sobre o assunto para se obterem mais informações. Arq Bras Endocrinol Metab. 2014;58(8):824-7 
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INTRODUCTION
T hyroid volume has been associated with multiple factors such as iodine deficiency and supply, body 
surface area (BSA), body mass index (BMI), age, gen-
der, smoking and genetic factors (1,2). Impaired fasting 
glucose (IFG), impaired glucose tolerance (IGT), and 
diabetes mellitus (DM) can be mentioned among the 
principal disorders of the glucose metabolism in which 
insulin resistance (IR) acts as a significant factor. The 
morphological and pathological changes in the thyroid 
gland induced by glucose metabolism disorders (GMD) 
have already been reported (3,4). Increased thyroid vo-
lumes were reported in patients with IR (3,4). Insulin 
resistance is associated with GMD and it is well known 
that, in the pathogenesis of DM, insulin resistance and 
compensatory hyperinsulinemia plays a pivotal role (5). 
Although a few studies showed an association be-
tween thyroid volume and GMD, especially type 1 
DM, data about the relationship between GMD and 
thyroid gland volume are rare (6,7). As thyroid volume 
is associated with IR, the relationship between thyroid 
volume and GMD should be investigated. We hypoth-
esized that increased in thyroid volume was associated 
with GMD (IFG, IGT and DM). 
SUBJECTS AND METHODS 
The study design is cross-sectional with retrospective 
data. We examined the files of 4,500 patients who were 
admitted or referred by other policlinics to the endocri-
nology policlinic for thyroid examination between June 
2003 – January 2009 and 2,630 patients aged between 
15-97 years were included after considering the exclu-
sion and inclusion criteria. The age, gender, and blood 
glucose characteristics of the patients were noted. Thy-
roid function was evaluated by measuring thyroid stim-
ulating hormone (TSH) using immunochemilumines-
cent assays by an automated analyzer (Immulite 2000; 
Diagnostic Products, Los Angeles, CA, USA). Serum 
glucose was measured by the glucose oxidase technique 
(Roche Diagnostics, Mannheim, Germany). The refer-
ences ranges for serum TSH were 0,35-4,94 (mIU/L). 
Glucose metabolism disorders were evaluated ac-
cording to the American Diabetes Association (ADA) 
2009 criteria (5). The categories of fasting plasma glu-
cose (FPG) values are as follows: FPG < 100 mg/dL 
normal fasting glucose; FPG 100-125 mg/dL IFG and 
FPG ≥ 126 mg/dL provisional diagnosis of diabetes. 
The corresponding categories when the oral glucose 
tolerance test (OGTT) is used are the following: 2-h 
postload glucose < 140 mg/dL normal glucose tol-
erance; 2-h postload glucose 140-199 mg/dL IGT 0 
and 2-h postload glucose ≥ 200 mg/dL provisional 
diagnosis of diabetes. The patients were classifed into 
groups as follows: patients with normal fasting glucose, 
patients with GMD (IFG and IGT) and patients with 
DM according to the fasting blood glucose and OGTT. 
Thyroid size was estimated by ultrasonography us-
ing a 10-MHz linear probe (Logiq 5 Pro, GE).
Medical Systems, WI, USA). The volumes of the 
thyroid glands and nodules were calculated according 
to the ellipsoid formula: volume (mL) = depth (cm) × 
width (cm) × length (cm) × π/6. Nodules were defined 
as solitary lesions distorting the uniform shape or echo 
pattern of the thyroid gland with a diameter of at least 
1 cm. The volume of nodules was not considered to-
gether with thyroid volumes.
Exclusion criteria were as follows: a history of neck 
irradiation, operation or fine-needle aspiration biopsy 
(FNAB), a history of thyroid disease, overt or subclini-
cal hypothyroidism and previous-thyroxine suppression 
therapy at any time. 
Statistical analysis of the acquired data was carried out 
with the SPSS 16.0 (SSPS Inc, Chicago, USA) for Win-
dows package program. As descriptive statistics, numeri-
cal values and percentiles were used for numeric data. 
The compliance of numerical values to normal distribu-
tion was evaluated with the One-Sample Kolmogorov-
Smirnov test. Since numerical values did not have a 
normal distribution, median and minimum-maximum 
values were employed and non-parametric tests were 
used. Spearman correlation analysis was used to verify 
the correlation between numerical variables. Intergroup 
comparisons for categorical values were performed with 
the Chi-Square test. Comparisons of non-parametric 
values among groups were performed by Kruskal Wal-
lis test and the Bonferroni adjustment Mann-Whitney 
U-test (for non-parametric variables) was used as a post 
hoc test for multiple comparisons between the groups. 
In all evaluations, results with p < 0.05 within a confi-
dence interval of 95% were deemed as statistically signifi-
cant. Multiple linear regression analysis was used for the 
assessment of independent predictors of thyroid volume. 
RESULTS
The study population included a total of 2,630 pa-
tients, 602 patients with GMD, 554 patients with DM 
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and 1,474 patients with normal glucose metabolism 
as a control group. Two thousand and seventy-six 
(78.9%) patients were female and 554 (21.1%) patients 
were male. The number of male patients in the control 
group, GMD group and DM group were 261 (17.7%), 
129 (21.4%) and 164 (29.6%) respectively. There was 
a significant difference between all groups according 
to gender (Table 1). The median ages for the control 
group, GMD group and DM group were 55 (15-91) 
years, 60 (27-97) years, and 65 (27-91) years respec-
tively and there was a statistically significant difference 
between the groups with regard to age and gender 
(p < 0.001, Table 1). TSH levels were similar in all 
groups [for control patients: 0.9 (0.1-28) (mIU/L), 
for GMD group: 1 (0.1-15) (mIU/L) and for DM 
group: 0.9 (0.1-28) (mIU/L) (p > 0.05, Table 1)]. 
The median total thyroid volumes for the patients with 
DM and GMD were significantly higher than that of 
the control group [22.5 (3-202) mL, 20.2 (4-190) 
mL, and 19.2 (3-168) mL respectively, p ≤ 0.001 for 
all parameters]. Also the median total thyroid volumes 
for patients with DM was significantly higher than that 
of the GMD group (p < 0.001, Table 1). According to 
the correlation analysis, thyroid volume was correlated 
with age (r = 0.92, p < 0.001) and TSH (r = 0.435, 
p < 0.001). The maximum nodule diameters of patients 
with DM and GMd were significantly higher than that 
of the control group (p < 0.001, Table 1). The maxi-
mum nodule diameter was similar in the patients with 
GMD and DM. Age, gender, TSH levels and GMD 
and DM diagnosis were independently correlated with 
thyroid volume (Table 2). 
Table 1. Clinical, laboratory and thyroid ultrasonography properties of 
patients
Controls  
(n = 1474)
GMD  
(n = 602)
DM  
(n = 554)
p
Male 261 (17.7%) 129 (21.4%) 164 (29.6%) < 0.001a,b,c
Age (year) 55 (15-91) 60 (27-97) 65 (27-91) < 0.001a,b,c
TSH (mIU/L) 0.9 (0.1-28) 1 (0.1-15) 0.9 (0.1-28) 0.511
Thyroid volume 
(mL)
19.2 (3-168) 20.2 (4-190) 22.5 (3-202) < 0.001a,b,c
Max nodule 
diameter (mm)
1.6 (0.2-6.9) 1.6 (0.3-8.3) 1.6 (0.4-7.5) 0.001a,b
(Data are given as median and minimum-maximum levels as appropriate). GMD: glucose 
metabolism disorders; DM: type 2 diabetes mellitus; TSH: thyroid stimulating hormone. 
a: significant difference between controls and patients with GMD, b: significant difference 
between controls and patients with type 2 DM, c: significant difference between patients with 
GMD and type 2 DM (One-Way ANOVA and Bonferroni test for comparision of non parametric 
variables and Chi-Square test for comparisons of categorical values).
Table 2. Multiple linear regression analysis for the assessment of 
independent predictors of thyroid volume
Thyroid volume
Beta t p
Age (year) 0.07 2.8 0.005
Gender (male) 0.232 9.1 < 0.001
TSH (mIU/L) 0.19 7.9 < 0.001
GMD vs. control 0.03 2.2 0.027
DM vs. control 0.05 2.8 0.004
TSH: thyroid stimulating hormone; GMD: glucose metabolism disorders; DM: type 2 diabetes 
mellitus.
DISCUSSION
The main result of our study was total thyroid volumes 
for patients with DM and GMD were significantly 
higher than that of the control group. GMD and thy-
roid disorders occur in the common endocrine diseases 
of the adult population. It is well known that, in the 
pathogenesis of DM, insulin resistance and compensa-
tory hyperinsulinemia play a pivotal role (5,8). 
Until now, only a few studies have investigated an 
association between thyroid volume and GMD. Rez-
zonico and cols. showed a positive association between 
IR and thyroid volume (4). Junik and cols. reported 
that the median thyroid volumes in patients with type 
1 and type 2 DM (in only 30 and 98 patients respec-
tively) were significantly higher than the control group 
(6). They also reported that TSH levels did not dif-
fer between type 2 DM and control cases; they were 
significantly lower than the controls in type 1 DM pa-
tients. Anil and cols. showed that patients with pre-di-
abetes and type 2 DM had larger thyroid volumes and 
higher risk for formation of thyroid nodules than the 
control group (9). They also reported that the serum 
TSH level was higher in patients with type 2 DM than 
in patients with pre-diabetes and in controls. In anoth-
er study, the authors demonstated that type 1 DM pa-
tients (65 type 1 patients and 65 control patients) had 
larger thyroid volumes compared with healthy controls 
with similar anthropometry (10). In these studies, the 
investigators speculated that thyroid autoimmunity 
and lower iodine ingestion have an important effect 
on the thyroid volume. 
In the current retrospective study, we determined a 
significant correlation between GMD/type 2 DM and 
elevated thyroid volume among patients who were re-
ferred for thyroid biopsy. Our study population con-
sisted of 602 patients with GMD and 554 patients with 
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DM, which is relatively large according to the studies 
mentioned above. Unlike those studies we did not find a 
relationship between serum TSH levels and the presence 
of GMD/type 2 DM (Table 1). Serum TSH levels were 
correlated with thyroid volume (r = 0.435, p < 0.001).
Progression of the thyroid cell cycle is dependent on 
joint activity of TSH and insulin/insulin-like growth fac-
tor-1 (IGF-1), all of which function as co-mitogenic fac-
tors (11). The main regulator of growth and differentia-
tion of thyroid cells is TSH (12). Therefore, serum TSH 
levels should be evaluated in the initial evaluation of a 
patient with a high thyroid volume. We found a signifi-
cant association between serum TSH levels and thyroid 
volume which is in accordance with studies done so far.
The most important effects of GMD leading to el-
evated risk are hyperinsulinemia, IR, and hyperglyce-
mia that can exist for years before and after diagnosis. 
Elevated insulin levels due to IR lead to an increase in 
IGF-1 levels (which is an important hypertrophic and 
progression factor for a series of cell types including 
thyroid cells). Experimental evidence showed that both 
insulin and IGF-1 modulated the regulation of thyroid 
gene expression and elevated insulin and/or glucose 
levels may lead to proliferation of thyroid cells by af-
fecting cellular energy metabolism (13,14).
Insulin also raises the mitogenic activity of growth fac-
tors (11). Although the proliferative properties of insulin 
and IGF-1 are known, the impact of these parameters on 
the total thyroid volume is unclear. We hypothesized that 
higher circulating levels of glucose, insulin and IGF-1 in 
the case of abnormal glucose metabolism may cause in-
creased thyroid proliferation and thyroid volume.
The most important limitation of our study was its ret-
rospective design. Several risk factors are influential both 
in diabetes and thyroid volume such as TSH, body weight, 
physical activity, alcohol use, nutrition style, and BMI. Be-
cause of the design of our study, we could not evaluate all 
these parameters. Our study was based on data acquired 
from a single center. 
In conclusion, we reported a positive correlation be-
tween GMD/type 2 DM and thyroid volume. Further 
controlled, prospective, randomized studies on this sub-
ject are required to gain more information. In a recently 
published systematic review, the authors reported that in-
dividuals with diabetes showed a borderline statistically 
significant increased risk of thyroid cancer compared with 
those without diabetes (15). According to our results, high 
thyroid volumes in patients with GMD and DM may be 
related with increased risk of malignancy in these patients. 
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